Andreas Port

532 total citations
15 papers, 435 citations indexed

About

Andreas Port is a scholar working on Molecular Biology, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Andreas Port has authored 15 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Pharmacology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Andreas Port's work include Pharmacogenetics and Drug Metabolism (3 papers), Renal Transplantation Outcomes and Treatments (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Andreas Port is often cited by papers focused on Pharmacogenetics and Drug Metabolism (3 papers), Renal Transplantation Outcomes and Treatments (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Andreas Port collaborates with scholars based in Germany, United States and Switzerland. Andreas Port's co-authors include Arne Ring, Ulrike Graefe‐Mody, Christian Friedrich, Atef Halabi, H.J. Woerle, Silke Retlich, Tim Heise, Stefan Hartmann, John M. Kovarik and Christiane Rordorf and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Annals of Oncology and Neuropharmacology.

In The Last Decade

Andreas Port

14 papers receiving 413 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andreas Port Germany	10	218	159	92	80	62	15	435
Theodore Sullivan United States	6	214 1.0×	129 0.8×	78 0.8×	58 0.7×	50 0.8×	11	515
Chika Tazawa Japan	11	135 0.6×	131 0.8×	165 1.8×	53 0.7×	50 0.8×	15	561
Ferhan Siddiqi Canada	11	91 0.4×	280 1.8×	28 0.3×	63 0.8×	18 0.3×	22	560
Matthew M. Goodman United States	14	351 1.6×	198 1.2×	133 1.4×	159 2.0×	68 1.1×	23	675
Q. Shao China	14	595 2.7×	409 2.6×	207 2.3×	249 3.1×	91 1.5×	31	914
Kuan-Lih Hsu Taiwan	8	148 0.7×	227 1.4×	41 0.4×	54 0.7×	44 0.7×	10	724
Viktor Růžička Czechia	11	166 0.8×	118 0.7×	31 0.3×	50 0.6×	72 1.2×	20	418
Marina Ivanovic United States	9	300 1.4×	178 1.1×	90 1.0×	276 3.5×	7 0.1×	18	627
Mayumi Mukai Japan	11	149 0.7×	179 1.1×	310 3.4×	43 0.5×	37 0.6×	20	594
Hameda B. Hussain United States	7	126 0.6×	218 1.4×	48 0.5×	114 1.4×	52 0.8×	7	470

Countries citing papers authored by Andreas Port

Since Specialization

Citations

This map shows the geographic impact of Andreas Port's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Port with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Port more than expected).

Fields of papers citing papers by Andreas Port

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Port. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Port. The network helps show where Andreas Port may publish in the future.

Co-authorship network of co-authors of Andreas Port

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Port. A scholar is included among the top collaborators of Andreas Port based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Port. Andreas Port is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Port, Andreas, et al.. (2025). Mice lacking the endocannabinoid-synthesizing enzyme NAPE-PLD exhibit sex-dependent dysregulations in responsiveness to oxycodone and a natural reward. Neuropharmacology. 278. 110573–110573.

Dyroff, Martin C., Andreas Port, Jennifer Dong, et al.. (2021). Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. Clinical and Translational Science. 14(6). 2420–2430. 11 indexed citations

Port, Andreas, et al.. (2021). Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8. Pharmacology Research & Perspectives. 9(5). e00842–e00842. 36 indexed citations

Marbury, Thomas, et al.. (2021). 1257P Effect of hepatic impairment on tepotinib pharmacokinetics. Annals of Oncology. 32. S987–S987. 1 indexed citations

Port, Andreas, et al.. (2020). P135 A phase I, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of M5049, a dual antagonist of TLR7/8, in healthy subjects. Poster presentations. A95.1–A95. 1 indexed citations

Graefe‐Mody, Ulrike, Christian Friedrich, Andreas Port, et al.. (2011). Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin ^*. Diabetes Obesity and Metabolism. 13(10). 939–946. 148 indexed citations

Friedrich, Christian, Andreas Port, Arne Ring, et al.. (2011). Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults. Clinical Drug Investigation. 31(9). 643–653. 22 indexed citations

Ring, Arne, et al.. (2011). The DPP‐4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. British Journal of Clinical Pharmacology. 72(1). 39–50. 26 indexed citations

Lam, Y. W. Francis, Larry Ereshefsky, Andreas Port, C. J. Timmer, & Peter Dogterom. (2009). Effects of Rifampin on the Disposition of Gepirone ER and Its Metabolites. 3. 1–7. 3 indexed citations

10.

Kovarik, John M., Stefan Hartmann, Michael G. Bartlett, et al.. (2007). Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharmaceutics & Drug Disposition. 28(2). 97–104. 40 indexed citations

11.

Bagchus, Wilma M., et al.. (2005). Pharmacokinetic Evaluation of Three Different Intramuscular Doses of Nandrolone Decanoate: Analysis of Serum and Urine Samples in Healthy Men. The Journal of Clinical Endocrinology & Metabolism. 90(5). 2624–2630. 39 indexed citations

12.

Kovarik, John M., et al.. (2002). Effect of Rifampin on Apparent Clearance of Everolimus. Annals of Pharmacotherapy. 36(6). 981–985. 63 indexed citations

13.

Kovarik, John M., et al.. (2002). Effect of Rifampin on Apparent Clearance of Everolimus. Annals of Pharmacotherapy. 36. 981–985. 3 indexed citations

14.

Port, Andreas, Lisa J. Benincosa, H. Fuder, et al.. (2001). An Overview of the Pharmacokinetics of Cilomilast (Ariflo®), a New, Orally Active Phosphodiesterase 4 Inhibitor, in Healthy Young and Elderly Volunteers. The Journal of Clinical Pharmacology. 41(9). 950–958. 19 indexed citations

15.

Zussman, Barry D., Lisa J. Benincosa, David J. Clark, et al.. (2001). An Overview of the Pharmacokinetics of Cilomilast (Ariflo®), a New, Orally Active Phosphodiesterase 4 Inhibitor, in Healthy Young and Elderly Volunteers. The Journal of Clinical Pharmacology. 41(9). 950–958. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact